Eurydice Angeli

Eurydice Angeli

Auto-generated profile, based on publicly available information

Eurydice Angeli

Department of Medical Oncology, Hôpital Avicenne, Bobigny, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BGBurak Gonullu
Burak Gonullu
EAEurydice Angeli
Eurydice Angeli
FPFrédéric Pamoukdjian
Frédéric Pamoukdjian
Guilhem BOUSQUETGuilhem BOUSQUET
Guilhem BOUSQUET
Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. However, the correlation between the HER2 copy number and the response rate to anti-HER2 remains unclear. Here, following the PRISMA method, we performed a meta-analysis in the neoadjuvant setting in breast cancer to study the association between the HER2 amplification level and the pathological complete response (pCR) to anti-HER2 therapies. Nine articles (four clinical trials, five observational studies) were retrieved after full-text screening, involving 11,238 women with locally advanced breast cancer in the neoadjuvant setting. The median HER2/CEP17 ratio cut-off value was 5.0 ± 5.0 (min-max = 1.0–14.0). For the overall population, the median pCR rate was 48% using the random effect model. The studies were categorized in quartiles as follows: ≤2 (Class 1); 2.1 to 5.0 (Class 2); 5.1 to 7.0 (Class 3); and >7.0 (Class 4). After grouping, the pCR rates were 33%, 49%, 57%, and 79%, respectively. When we excluded the study by Greenwell et al., which accounted for 90% of the patients, using the same quartiles, we still observed an increasing rate of pCR as the HER2/CEP17 ratio increased. This is the first meta-analysis demonstrating the relationship between the HER2 amplification level and the percentage of pCR in the neoadjuvant setting among women with HER2-overexpressing breast cancer, with potential therapeutic applications.

1 February 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
DHDIADDIN HAMDAN
DIADDIN HAMDAN
LMLaetitia Marisa
Laetitia Marisa
CTCamille Tlemsani
Camille Tlemsani
EAEurydice Angeli
Eurydice Angeli
MSMichael Soussan
Michael Soussan
Guilhem BOUSQUETGuilhem BOUSQUET
Guilhem BOUSQUET

19 October 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
EAEurydice Angeli
Eurydice Angeli
AGAlexander Ariel Padrón González
Alexander Ariel Padrón González
DHDiaddin Hamdan
Diaddin Hamdan
GPGabriel Pop
Gabriel Pop
GFGéraldine FALGARONE
Géraldine FALGARONE
GBGuilhem Bousquet
Guilhem Bousquet

11 June 2026 in The Breast
Verified
Journal Article
Open access
TSTal Sella
Tal Sella
FDFrederieke van Duijnhoven
Frederieke van Duijnhoven
HWhans wildiers
hans wildiers
CVClaudio Venieri
Claudio Venieri
KPKatarzyna Pogoda
Katarzyna Pogoda
SAShai Ayelet
Shai Ayelet
Use of taxane-only chemotherapy for stage I HR+/HER2+ breast cancer has increased, potentially preserving ovarian function and shifting endocrine therapy (ET) strategies. Outcomes in premenopausal women were not defined. Patients ≤45 years with stage I HR+/HER2+ breast cancer were identified from a multicenter registry. IDFS was assessed by chemotherapy and ET. Thirteen IDFS events (4 distant) occurred among 244 patients. Six-year IDFS was 95.5% (multiagent chemotherapy) and 94.1% (taxane-only) (p = 0.56), and 95.9%, 93.8%, and 96.9% with tamoxifen, tamoxifen + OFS, and AI + OFS (p = 0.56). Outcomes were excellent regardless of chemotherapy or ET, suggesting limited incremental benefit from treatment intensification.

30 April 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JFJelena Filipovic
Jelena Filipovic
EAEmma Anjorand
Emma Anjorand
LMLaetitia Marisa
Laetitia Marisa
EAEurydice Angeli
Eurydice Angeli
CDClaire Davoine
Claire Davoine
DHDiaddin Hamdan
Diaddin Hamdan
While precision medicine is increasingly available, the first trials produced disappointing results, partly due to limitations of molecular profiling to mutational analyses. Here, we report a monocentric real-life experience of an integrative and interactive approach using a dedicated genomic platform for metastatic cancer patients in a situation of therapeutic failure. From October 2020 to May 2024, 1049 patients with cancers in a situation of treatment failure have been prospectively enrolled in the national program "France Médecine Génomique 2025", 73 patients from Avicenne Hospital. Data from 20 patients with hepatocellular carcinoma were previously reported. We report here data from 27 among the remaining patients. For each patient, Sequencing Omics Information Analysis platform performed tumor and germline whole-genome, whole-exome sequencing, and RNAseq to receive tailored treatments. Tumor responses and survival data were systematically collected. Twenty-seven patients with locally advanced or metastatic cancers from twenty histological types received 32 treatment lines, 37.5% being ESCAT-I/II (high-proof efficacy level). 40% of lines were guided in part by transcriptomic analyses. Median treatment duration was 15.6 months, and median survival was not linked to ESCAT category. SeqOIA-tailored treatment outperformed previous lines, with a Growth Modulation Index≥ 1.33 for 70% of the patients. 69% of treatment lines were combined therapies, showing greater clinical benefit (86% vs. 54%, P < 0.01) and longer survival than monotherapies (15.8 vs. 13.9 months, HR=0.77, P = 0.01). Our monocentric real-life experience of interactive multidisciplinary care based on integrative genomic analyses improved survival of metastatic cancer patients using off-label combined personalized therapies.